酪氨酸激酶抑制剂治疗中Ph+急性淋巴细胞白血病患者接受BCR-ABL特异性T细胞治疗
研究探讨体外扩增/致敏p190BCR-ABL特异性T细胞并过继回输治疗复发Ph+ ALL的可行性。从患者和健康供者制备具有抗白血病活性的临床级BCR-ABL特异性细胞毒性T淋巴细胞(CTL),治疗3例Ph+ ALL患者,除1例因血液学复发治疗者出现II级皮肤移植物抗宿主病外未见输注后毒性,所有患者均获分子学或血液学完全缓解(CR)。
要点
- 可从Ph+ ALL患者和健康供者制备临床级p190BCR-ABL特异性CTL
- 3例Ph+ ALL患者接受自体或异基因p190BCR-ABL特异性CTL治疗
- 除1例血液学复发者出现II级皮肤GVHD外,未见输注后毒性
核心结论
- p190BCR-ABL特异性CTL能够在体内控制治疗难治性Ph+ ALL,支持在Ph+ ALL中开发BCR-ABL CTL过继免疫治疗策略。
研究设计与样本
- 研究体外用负载p190BCR-ABL肽(源自BCR-ABL连接区及可变剪接)的树突状细胞刺激扩增/致敏p190BCR-ABL特异性T细胞,并过继回输至复发患者。
- 从Ph+ ALL患者和健康供者制备具有抗白血病活性的临床级BCR-ABL特异性细胞毒性T淋巴细胞(CTL)。
- 治疗3例Ph+ ALL患者,回输自体或异基因p190BCR-ABL特异性CTL。
主要发现
- 3例Ph+ ALL患者接受自体或异基因p190BCR-ABL特异性CTL治疗,除1例因血液学复发治疗者出现II级皮肤移植物抗宿主病外,未见输注后毒性。
- 所有患者在T细胞治疗后、骨髓中出现p190BCR-ABL特异性T细胞后,均达到分子学或血液学完全缓解(CR)。
关键数值与推荐
- 3例Ph+ ALL患者接受自体或异基因p190BCR-ABL特异性CTL治疗。
- 1例因血液学复发治疗的患者出现II级皮肤移植物抗宿主病。
- 所有患者达到分子学或血液学完全缓解(CR)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the emergence of bone marrow (BM)-resident p190BCR-ABL-specific T lymphocytes has been correlated with hematologic and cytogenetic remissions in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) undergoing maintenance tyrosine-kinase inhibitor treatment, little is known about the possibility of culturing these cells ex vivo and using them in T-cell therapy strategies. We investigated the feasibility of expanding/priming p190BCR-ABL-specific T cells in vitro by stimulation with dendritic cells pulsed with p190BCR-ABL peptides derived from the BCR-ABL junctional region and alternative splicing, and of adoptively administering them to patients with relapsed disease. We report on the feasibility of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity, from Ph+ ALL patients and healthy donors. We treated 3 patients with Ph+ ALL with autologous or allogeneic p190BCR-ABL-specific CTLs. No postinfusion toxicity was observed, except for a grade II skin graft-versus-host disease in the patient treated for hematologic relapse. All patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emergence of p190BCR-ABL-specific T cells in the BM. Our results show that p190BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph+ ALL in vivo, and support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph+ ALL.
引用
- Comoli P, Basso S, Riva G, et al. BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. Blood. 2016. PMID: 27927646. doi:10.1182/blood-2016-07-731091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。